4-(叔丁氧基)-4-氧代-3-苯基丁酸 | 104465-81-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: 4-(叔丁氧基)-4-氧代-3-苯基丁酸
• 英文名称: 4-(tert-butoxy)-4-oxo-3-phenylbutanoic acid
• 英文别名: 3-Boc-Amino-3-Phenylpropioinic Acid；4-[(2-methylpropan-2-yl)oxy]-4-oxo-3-phenylbutanoic acid
• CAS: 104465-81-8
• 化学式: C₁₄H₁₈O₄
• 分子量: 250.295
• InChiKey: YZFRBARGDLOFTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,6-二甲基苯酚 、 4-(叔丁氧基)-4-氧代-3-苯基丁酸 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以70%的产率得到(+/-)-1-tert-butyl 4-(2,6-dimethylphenyl) 2-phenylsuccinate
  参考文献：
  名称：

  Preparation of Chiral 3-Arylpyrrolidines via the Enantioselective 1,4-Addition of Arylboronic Acids to Fumaric Esters Catalyzed by Rh(I)/Chiral Diene Complexes

  摘要：

  A highly efficient rhodium-catalyzed protocol for the preparation of 2-arylsuccinic esters and 3-arylpyrrolidines of high optical purity has been achieved. In the presence of 1 mol % of a chiral diene/Rh(I) catalyst, asymmetric addition of various arylboronic acids to di-fert-butyl fumarate (3c) provides the corresponding adducts in up to 99% yield and 94 -> 99.5% ee. Excellent enantioselectivities were also observed in the regio- and enantioselective conjugate addition of phenylboronic acid (4a) to compound 3e.

  DOI：

  10.1021/ol300980k
• 作为产物：
  描述：

  (+/-)-1-tert-butyl 4-methyl 2-phenylsuccinate 在 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 15.0h， 以95%的产率得到4-(叔丁氧基)-4-氧代-3-苯基丁酸
  参考文献：
  名称：

  Preparation of Chiral 3-Arylpyrrolidines via the Enantioselective 1,4-Addition of Arylboronic Acids to Fumaric Esters Catalyzed by Rh(I)/Chiral Diene Complexes

  摘要：

  A highly efficient rhodium-catalyzed protocol for the preparation of 2-arylsuccinic esters and 3-arylpyrrolidines of high optical purity has been achieved. In the presence of 1 mol % of a chiral diene/Rh(I) catalyst, asymmetric addition of various arylboronic acids to di-fert-butyl fumarate (3c) provides the corresponding adducts in up to 99% yield and 94 -> 99.5% ee. Excellent enantioselectivities were also observed in the regio- and enantioselective conjugate addition of phenylboronic acid (4a) to compound 3e.

  DOI：

  10.1021/ol300980k

文献信息

• Methods of Inhibiting Metastasis from Cancer
  申请人：Salvino Joseph M.

  公开号：US20120141471A1

  公开（公告）日：2012-06-07

  The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX 3 CR1 or fractalkine antagonist.

  本发明涉及一种用于预防或治疗被诊断为癌症的患者中的转移的组合物。本发明还包括一种用于预防或治疗被诊断为癌症的患者中的转移的方法，其中该方法包括向需要该药物的患者投与至少一种药用制剂，该制剂包括至少一种药用载体和至少一种CX3CR1或fractalkine拮抗剂的有效量。
• Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same
  申请人：Drexel University College of Medicine Philadelphia Health & Education Corporation d/b/a

  公开号：US20130156761A1

  公开（公告）日：2013-06-20

  The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX 3 CR1 or fractalkine antagonist.

  本发明涉及一种对已被诊断患有癌症的受试者预防或治疗转移的有用组合物。本发明还涉及一种预防或治疗已被诊断患有癌症的受试者的转移的方法，其中该方法包括向需要该药物的受试者施用至少一种药物制剂，该药物制剂包括至少一种药用载体和至少一种CX3CR1或fractalkine拮抗剂的有效量。
• Compounds useful for inhibiting metastasis from cancer and methods using same
  申请人：Drexel University

  公开号：US10414771B2

  公开（公告）日：2019-09-17

  The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX3CR1 or fractalkine antagonist.

  本发明包括可用于预防或治疗确诊癌症患者转移的组合物。本发明还包括预防或治疗被诊断患有癌症的受试者的转移的方法，其中该方法包括向需要该方法的受试者施用有效量的药物制剂，该药物制剂包含至少一种药学上可接受的载体和至少一种CX3CR1或fractalkine拮抗剂。
• METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF alpha v beta 5 MEDIATED ANGIOGENESIS
  申请人：The Scripps Research Institute

  公开号：EP0907661A1

  公开（公告）日：1999-04-14
• EP0907661A4
  申请人：——

  公开号：EP0907661A4

  公开（公告）日：2000-07-26